Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Consano BioConsano Bio Announces Peer-Reviewed Publication Supporting the Therapeutic Potential of C-1101 in Chronic, Painful Lumbosacral Radiculopathy (LSR) or Chronic SciaticaResearch published in Frontiers in Bioengineering and Biotechnology demonstrated C‑1101 reduced inflammation and tissue breakdown while activating repair pathways — acting on the disease, not just the pain — in a nonclinical study Pain sensitivity also decreased in a second species,...
- NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the potential of troculeucel, the Company’s lead investigational program, for the treatment of neurodegenerative diseases at Biologics Manufacturing Korea 2026, taking place September 17-18, 2026, in Incheon, South Korea.
- Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of DirectorsCandel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Martine Zimmermann, PharmD, to the Company’s Board of Directors (Board) effective September 8, 2026.
- Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –
- Glenmark PharmaceuticalsGlenmark Pharmaceuticals and South Piedmont Community College Launch Aseptic Training Facility in Monroe, N.C.$2.7 million partnership advances workforce development to prepare the next generation of pharmaceutical manufacturing professionals in North Carolina. — Glenmark Pharmaceuticals Inc. USA (Glenmark) joined South Piedmont Community College to...
- Aprea TherapeuticsAprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceAprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.
- Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of DirectorsChair of Translational Neuro-Oncology at the University of Manchester, previously a member of the Company's Scientific Advisory Board, elected at the 2026 Annual General Meeting
- medmix AGmedmix' Drug Delivery ("Haselmeier") to Support the Development of Xeris Pharmaceuticals' XP-8121 with D-Flex(TM) Pen Injectormedmix’ Drug Delivery (“Haselmeier”) announces its collaboration with Xeris Pharmaceuticals to support the development of Xeris’ XP-8121 product candidate, an investigational once-weekly subcutaneous levothyroxine therapy in development for the treatment of hypothyroidism. XP-8121 combines a proprietary high-concentration XeriSol® levothyroxine formulation with an adjustable pen injector...
- VVMF, Australia's First Viral Vector CDMO Receives TGA Manufacturing LicenceVVMF has been granted a Licence to Manufacture Therapeutic Goods (GMP licence) from the Therapeutic Goods Administration (TGA) for their site in Sydney.
- U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatmentsCompanies: Roche HoldingBasel, 10 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The filing acceptance is based on positive results from the Phase III METEOROID study, which showed that Enspryng provided consistent, clinically meaningful improvements for people living with MOGAD.1 This marks the second FDA Priority Review for Enspryng, following the one granted for thyroid eye disease (TED) in June 2026. The FDA is expected to make a decision on approval in MOGAD by 10 January 2027.
- Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPRClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NasdaqGS: CAPR), if they purchased Capricor securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.
- Robbins Geller Rudman & Dowd LLPREGN MONDAY DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action LawsuitThe law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until September 14,...